



# Drug Resistant Pulmonary Tuberculosis

2023 Challenging Case Session

February 24, 2023

Dr I Villarosa, M Sherry RN, A Spaulding MPH

# History and Physical

## *History*

34 y/o Philippine F, in U.S. since 2017, No TB contact

*CC:* cough for 1 year, pink tinged sputum, 5 lb weight loss

*Past Med Hx:* DM Type 2, asthma, Covid PNA Dec 2021.

Nonsmoker. Previous nurse in the Philippines. Stay at home mother. Lives with husband, 8 y/o & 2 y/o son, and brother.

No sick family members.

*Meds:* metformin, albuterol inhale

*Physical Exam:* Lungs clear. Afebrile.

## *Labs:*

Covid test Neg. Pos QFT. HIV NR. WBC 16. Glc 301 HbA1c: 11

HCG: positive. 5 weeks AOG by LMP.


OB US: gestation 6 wks. Fetal bradycardia.

Pregnancy unknown to the patient

# VUMC CXR 5/2

CXR:  
cavitary  
lesion in  
R midlung

cavitary lesion  
R lower lung



# Treatment

Sputum smear <1, PCR pos MTB, rifampin resistant.

CDC MDDR and FL SNTC: resistant to RIF, INH

Sensitive to PZA, EMB and Ethionamide

Diagnosis: Multidrug resistant TB (MDR) Pulmonary TB

Later: SNTC : Resistant to Capreomycin

No mutation to BQ, Linezolid, fluoroquinolones, EMB

Diagnosis changed to: ***Pre-extensively DRTB (pre-XDR-TB)***

MDR: R to INH and rifampin & R to Fluoroquinolone

or **MDR & R to any 2<sup>nd</sup> line injectable aminoglycoside**

Started BPaL: Bedaquiline (BQ), Pretomanid, Linezolid

# Outcome

Unfortunately, the baby did not survive.

BPaL initiation: minimum issues :

mild HA, diarrhea x 1 day, heartburn x few days

mild ALT elevation: 54 (N: 5-50)

WBC normalized. CXR improved. BPaL drug levels normal.

Sputum culture converted 2 weeks after start of tx.

Completed 26 weeks BPaL.

Post treatment followup recommendations per SNTC protocol: 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24 months.

On 3<sup>rd</sup> month post treatment. Currently still doing well.

*Thank you!*